

The Manager
 Company Announcements Office
 ASX Limited

LBT BEGINS KEY U.S. TRIAL OF APAS TECHNOLOGY

Albuquerque, New Mexico, 9 June 2015: Australian medical technology company LBT Innovations Limited (ASX: LBT) has commenced the United States phase of the clinical trial programme for its pioneering culture-plate intelligent image analysis technology, APAS® (Automated Plate Assessment System).

The trial now underway at TriCore Reference Laboratories in New Mexico is in support of LBT's 510(k) *de novo* submission to the U.S. Food and Drug Administration (FDA), which must approve APAS before it can be distributed commercially in the United States.

The trial will test the efficacy of APAS in screening for the presence of disease-causing pathogens in urine samples from approximately 5,700 patients. Urine samples represent approximately 55% of all the samples analysed in microbiology laboratories worldwide. Modules for other specimen types are being developed.

APAS is currently being incorporated into new laboratory instruments under the supervision of LBT's joint venture partner. Including an automated culture plate reader and an automated-incubator, these instruments will automatically generate laboratory reports and sort culture plates for the next step in the workflow.

APAS will be brought to market through the LBT / Hettich joint venture company, Clever Culture Systems AG, which continues to progress discussions with leading diagnostic companies for the global distribution of APAS instruments.

– ENDS –

About TriCore

Founded in 1998 and headquartered in Albuquerque, New Mexico USA, TriCore Reference Laboratories is a community-based, independent, clinical reference laboratory that provides full-service, state-of-the-art laboratory tests to health care professionals and their patients throughout New Mexico and the Southwest. TriCore offers more than 1,500 laboratory tests ranging from routine to highly specialized. TriCore participates in scientific research through collaboration with the University of New Mexico and numerous national and international biotech firms. TriCore is an ISO 15189 medical laboratory.

For more information about TriCore Laboratories, visit www.TriCore.org

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Clever Culture Systems AG	Media Relations
Lusia Guthrie CEO, LBT Innovations Tel: +61 (0)8 8227 1555 E: lusia@lbtinnovations.com	Peter Bradley General Manager, CCS Tel: +61 (0)8 8227 1555 E: pbradley@cleverculturesystems.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au